Understanding Pharmacokinetics: Cmax, Tmax, AUC, and Half-Life

The short version

When a drug enters your body, its concentration changes over time: it rises as the drug is absorbed, peaks, and then falls as the body eliminates it. Pharmacokinetics (PK) is the study of that curve. The parameters in this guide are the standard measurements used to describe that curve: how high it peaks (Cmax), when it peaks (Tmax), how much area is under it (AUC), and how quickly it falls (half-life). Understanding these numbers lets you read a drug trial with a clearer eye.

Cmax: peak plasma concentration

Cmax is the highest plasma concentration a drug reaches after a single dose. It depends on two things: how much drug is given (dose) and how fast it is absorbed. A drug injected directly into a vein reaches its Cmax almost instantly. A drug given by subcutaneous injection must first diffuse from the injection site into local capillaries, so Cmax comes later and is lower than the equivalent intravenous dose.^[1]

Cmax matters clinically because many side effects are concentration-dependent. If Cmax is too high, a drug may cause toxicity even if its average concentration is therapeutic. For GLP-1 receptor agonists, nausea is more likely near the peak concentration, which is one reason that slow-release formulations and gradual dose escalation schedules are used.^[5]

Tmax: time to peak

Tmax is simply the time at which Cmax occurs. It is mainly a measure of absorption speed. A rapidly absorbed drug (e.g., an oral tablet that dissolves quickly) has a short Tmax, often 1 to 2 hours. A subcutaneous depot or a slow-release formulation has a longer Tmax.

For once-weekly peptide drugs like semaglutide and tirzepatide, Tmax after subcutaneous injection is typically 1 to 3 days, reflecting the time needed for the drug to diffuse from the subcutaneous depot into the bloodstream and distribute through tissue.^[3][4]This extended absorption phase is itself a pharmacokinetic advantage: it blunts the peak-to-trough ratio and keeps concentrations more stable throughout the dosing week.

AUC: area under the curve

AUC stands for "area under the concentration-time curve." It is calculated by integrating the plasma concentration curve from the time of dosing to a specified endpoint (often infinity, written AUC_0-∞, or to the last measurable concentration, written AUC_0-t). AUC represents the total drug exposure the body experienced during that period, expressed in units like ng·h/mL.^[1]

AUC is the pharmacokinetically most important single number for most drugs because it correlates with pharmacological effect (assuming the drug produces its effect in proportion to exposure) and with the likelihood of adverse effects. Bioavailability (the fraction of a dose that reaches the systemic circulation) is calculated by comparing the AUC of a non-intravenous route to the AUC of the intravenous route at the same dose.

The fundamental relationship between AUC, dose, and drug clearance is:

where CL is clearance (discussed below). This relationship means that if clearance is halved (for example, by renal impairment reducing the excretion of a renally cleared drug), AUC doubles at the same dose, which may require dose adjustment.^[6]

Half-life: the elimination clock

The terminal half-life (t½) is the time it takes for the plasma concentration to fall by half during the elimination phase (after absorption and distribution are complete). It is the most commonly cited pharmacokinetic parameter in drug labeling and trial reports.

The mathematical relationship between half-life, volume of distribution, and clearance is:

This equation has an important practical implication: half-life is determined by both how much the drug distributes into tissues (Vd) and how efficiently the body clears it. A drug can have a long half-life because it clears slowly (low CL) or because it distributes extensively into tissues (high Vd) or both.^[7]

Half-life determines the appropriate dosing interval. In general, dosing every one half-life keeps fluctuations between doses manageable. Semaglutide's half-life of approximately 165 hours (about 7 days) is what makes once-weekly dosing pharmacologically sensible.^[3]

Steady state: when accumulation stops

When a drug is dosed repeatedly, concentrations build up until the amount eliminated between doses equals the amount absorbed from each dose. This equilibrium is called steady state. Under first-order kinetics, steady state is reached after approximately 4 to 5 half-lives of repeated dosing, regardless of dose or dosing interval.^[1]

For a drug with a 7-day half-life (like semaglutide), steady state is reached after 4 to 5 weeks of once-weekly dosing. This is why efficacy trials for weekly GLP-1 receptor agonists typically run for at least 12 weeks before evaluating the primary endpoint: the first several weeks represent a ramp-up toward steady state rather than the drug's true steady-state pharmacological effect.

Volume of distribution and clearance

Volume of distribution (Vd) is a mathematical construct, not a real physiological volume. It represents the apparent volume of body fluid that would be needed to contain the entire dose at the measured plasma concentration:

where C₀ is the initial plasma concentration after intravenous dosing. A Vd of 5 liters suggests the drug stays mostly in plasma (roughly the plasma volume of an adult). A Vd of 200 liters means the drug distributes extensively into tissues and the plasma concentration is a small fraction of total body drug content. Lipophilic drugs have larger Vd.^[6]

Clearance (CL) is the volume of plasma completely cleared of drug per unit time (mL/min or L/h). It is the rate at which the body eliminates drug. Clearance occurs via multiple routes: renal (glomerular filtration, tubular secretion), hepatic (metabolism, biliary excretion), and for large peptides, proteolytic degradation. For tirzepatide, clearance is approximately 0.061 L/h, contributing to its extended half-life.^[8]

Why these parameters matter in special populations

PK parameters are not static: they change with body size, age, organ function, and drug interactions. The practical implications follow directly from the formulas above:

• Renal impairment: if a drug is renally cleared, CL falls with declining GFR, AUC rises, and accumulation may cause toxicity. Dose reduction or extended dosing intervals may be needed.
• Hepatic impairment: for drugs metabolized by the liver, hepatic impairment reduces CL, again raising AUC. Many peptide drugs are not substantially hepatically metabolized (they are degraded by proteases throughout the body), so hepatic impairment has less effect on their PK than for small-molecule drugs.
• Body weight: Vd often scales with body weight, particularly for drugs that distribute into fat. Higher body weight typically increases Vd and may reduce Cmax at the same dose. GLP-1 receptor agonist trials often show modestly lower exposure at higher baseline weights, a factor that can complicate exposure-response analysis.^[5]
• Age: older adults often have reduced renal and hepatic function, lower total body water, and altered protein binding, all of which can shift PK parameters from those measured in younger trial populations.

Applying these concepts when reading a trial

When you encounter PK data in a paper or supplement, the following questions help orient your interpretation:

1. Was Cmax high enough to be pharmacologically active? Was it so high that toxicity became concentration-driven?
2. Does the Tmax make sense for the route? A very long Tmax for an oral drug might indicate formulation problems; a short Tmax for a subcutaneous depot might indicate leakage rather than slow release.
3. Is AUC proportional to dose? Linear PK means doubling the dose doubles AUC. Non-linearity (saturable absorption or saturable clearance) can mean the drug accumulates faster than expected at higher doses.
4. How many half-lives elapsed before steady-state measurements were taken? Comparing week-2 concentrations to steady-state concentrations from a different trial can be misleading.
5. Were PK samples taken in a population similar to the patients the reader cares about? PK parameters from healthy volunteers may not apply to patients with renal or hepatic impairment.